{"id":"https://openalex.org/W367299136","doi":null,"title":"Erlotinib in non-small-cell lung cancer patients from Hospital Fernado Fonseca","display_name":"Erlotinib in non-small-cell lung cancer patients from Hospital Fernado Fonseca","alternate_titles":[],"publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W367299136","mag":"367299136"},"language":"en","primary_location":{"id":"pmh:oai:repositorio.hff.min-saude.pt:10400.10/897","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10400.10/897","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"conference object"},"parent_works":[],"lineage":["https://openalex.org/W367299136"],"child_works_count":0,"type":"conference-paper","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/10400.10/897","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101982791","display_name":"Juliana Ruiz Fernandes","orcid":"https://orcid.org/0000-0003-2127-8493","observed_orcids":["https://orcid.org/0000-0003-2127-8493"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Juliana Ruiz Fernandes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2127-8493","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041342703","display_name":"Pilar Frade","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P Frade","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083763012","display_name":"Sofia Teixeira","orcid":"https://orcid.org/0000-0002-4086-0975","observed_orcids":["https://orcid.org/0000-0002-4086-0975"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sofia Teixeira","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4086-0975","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110249693","display_name":"R Afonso","orcid":"https://orcid.org/0009-0005-9952-8124","observed_orcids":["https://orcid.org/0009-0005-9952-8124"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Afonso","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.0323,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.83474576,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9139999747276306},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.9190000295639038},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9639999866485596},{"id":"https://openalex.org/keywords/egfr-activating-mutations","display_name":"EGFR activating mutations","score":0.7739999890327454},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.5130000114440918},{"id":"https://openalex.org/keywords/egfr-mutation-status","display_name":"EGFR mutation status","score":0.4620000123977661},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.7519999742507935},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.503000020980835}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8738090991973877},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7178094387054443},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6407175064086914},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4249013066291809},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33880096673965454},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1075262725353241}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:repositorio.hff.min-saude.pt:10400.10/897","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10400.10/897","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"conference object"},{"id":"mag:367299136","doi":null,"is_oa":false,"landing_page_url":"https://repositorio.hff.min-saude.pt/bitstream/10400.10/897/1/poster%20EAHP%202013%20erlotinib.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:repositorio.hff.min-saude.pt:10400.10/897","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10400.10/897","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"conference object"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W367299136.pdf","grobid_xml":"https://content.openalex.org/works/W367299136.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2004844396","https://openalex.org/W7099879144","https://openalex.org/W2354127646","https://openalex.org/W2346455687","https://openalex.org/W2326412200","https://openalex.org/W2970400887","https://openalex.org/W2074471209","https://openalex.org/W169630847","https://openalex.org/W2382728708","https://openalex.org/W2140669653"],"abstract_inverted_index":{"INTRODUTION:":[0],"The":[1,227,237],"oral":[2,359],"epidermal":[3,360],"growth":[4,361],"factor":[5,362],"receptor":[6,363],"(EGFR)":[7],"tyrosine-kinase":[8,364],"inibitor":[9],"(TKI)":[10],"erlotinib":[11,72,473,518],"is":[12,73,115,119,287,296,367,388,395],"an":[13],"established":[14],"second-line":[15,39,522],"treatment":[16,443,523],"for":[17,282,291,353],"advanced":[18,36,354,445,479],"non-small-cell":[19,446,480,528],"lung":[20,447,481,529],"cancer":[21,482,530],"(NSCLC).1":[22],"Erlotinib":[23,90,127,139,167,200,214,258,274,285,294,418,440],"delays":[24],"disease":[25,222,351],"progression":[26,56,223],"and":[27,59,169,189,192,259,515],"increases":[28],"survival":[29,58,205],"after":[30,170],"first-line":[31],"chemotherapy":[32,78,255,266,520],"in":[33,62,142,419,444,475,521],"patients":[34,147,233,250,271,286,295,304,313,356,477,525],"with":[35,43,52,71,88,100,336,397,472,478,526,531],"NSCLC":[37,146,162,355],"as":[38,129,150,210,275,338,369,378,441],"therapy.2":[40],"Maintenance":[41],"therapy":[42,70,373],"erlotinib,":[44],"when":[45,148],"compared":[46,471],"to":[47,92,110,217,321,326],"placebo,":[48],"could":[49,347],"be":[50,348],"associated":[51,87],"a":[53,94,120,276,349,370,379,449,486,535],"significantly":[54],"longer":[55],"free":[57],"tolerability":[60],"mainly":[61],"EGFR":[63,195,309,317,385,398],"activating":[64,318],"mutation":[65,319],"tumours.3":[66],"However":[67],"second":[68,130,151,283,371],"line":[69,131,134,154,278,284,293,372,381],"not":[74],"more":[75],"effective":[76],"than":[77,98],"(pemetrexed":[79],"or":[80,152,224],"other).4,5":[81],"In":[82],"terms":[83],"of":[84,122,126,220,230,248,302,375,404,485,517,524],"traditional":[85],"toxicities":[86],"chemotherapy,":[89,99],"seems":[91,391],"have":[93,158,165,185,272,322],"better":[95,350],"safety":[96,516],"profile":[97,141],"no":[101],"haematological":[102],"toxicities,":[103],"the":[104,211,218,330,358],"most":[105,238,331],"common":[106,239,332],"event":[107,335],"was":[108,208,234,242,329],"mild":[109],"moderate":[111],"skin":[112],"rash":[113],"which":[114,207],"relatively":[116],"manageable.5":[117],"There":[118],"lack":[121],"evidence":[123],"regarding":[124,308],"efficacy":[125,394],"used":[128,149],"versus":[132,519],"third":[133,153,292,380],"therapy.":[135,155,279,382],"OBJECTIVES:":[136],"To":[137,198],"compare":[138],"effectiveness":[140,201],"Hospital":[143],"Fernando":[144],"Fonseca":[145],"METHODS:":[156],"We":[157],"followed":[159],"up":[160],"30":[161,232],"patients,":[163],"who":[164,314],"done":[166,273],"before":[168,257,268],"other":[171],"approved":[172],"chemotherapies,":[173],"during":[174],"14":[175],"months":[176],"starting":[177],"from":[178,213],"June":[179],"2011.":[180],"During":[181],"this":[182],"period":[183],"we":[184,202],"collected":[186],"patient\u2019s":[187],"demographics":[188],"baseline":[190],"characteristics":[191,406],"also":[193],"their":[194],"mutational":[196,310,386],"status.":[197],"determine":[199],"calculated":[203],"progression\u2013free":[204],"(PFS)":[206],"defined":[209],"time":[212],"therapeutic":[215],"initiation":[216],"date":[219],"documented":[221],"death.":[225],"RESULTS:":[226],"median":[228],"age":[229],"our":[231,249,303],"62,5":[235],"years.":[236],"pathological":[240],"subtype":[241],"adenocarcinoma":[243],"(66,7":[244],"%).":[245],"46,6":[246],"%":[247,261,301],"had":[251,262,305],"received":[252,263],"one":[253],"prior":[254,265],"regimen":[256,267],"36,6":[260],"two":[264],"Erlotinib.":[269,327],"Two":[270],"first":[277],"Median":[280],"PFS":[281],"18,7":[288],"weeks":[289],"while":[290],"12,3":[297],"weeks.":[298],"Only":[299],"50":[300],"available":[306],"information":[307],"status;":[311],"however":[312],"harbor":[315],"tumor-associated":[316],"seem":[320],"higher":[323],"response":[324],"rates":[325],"Rash":[328],"treatment-related":[333],"adverse":[334],"Erlotinib,":[337],"expected.":[339],"CONCLUSIONS:":[340],"Our":[341],"results":[342,484],"show":[343],"that":[344,392],"maybe":[345],"there":[346],"outcome":[352],"if":[357],"inhibitor":[365],"(Erlotinib)":[366],"administered":[368],"instead":[374],"using":[376],"it":[377,390],"As":[383],"far":[384],"status":[387],"concerned":[389],"enhanced":[393],"related":[396],"mutation-positive":[399],"disease.":[400],"REFERENCES:":[401],"1-":[402],"Summary":[403],"product":[405],"-":[407],"Tarceva\u00a9":[408],"2-":[409],"Shepherd":[410],"FA,":[411],"Pereira":[412],"J,":[413],"Ciuleanu":[414,434,506],"T,":[415,435,507],"et":[416,438,467,512],"al.":[417,439,468,513],"previously":[420],"treated":[421],"Non-small-cell":[422],"Lung":[423],"Cancer.":[424],"N":[425],"Eng":[426],"J":[427],"Med":[428],"2005;":[429],"353:123-132.":[430],"3-":[431],"Cappuzzo":[432],"F,":[433],"Stelmakh":[436,508],"l,":[437,509],"maintaenance":[442],"cancer:":[448],"multicentre,":[450,537],"randomized,":[451],"placebo-controlled":[452],"phase":[453,488,539],"3":[454,540],"study.":[455,541],"Lancet":[456,542],"Oncol":[457,499,543],"2010;":[458,500],"11:521-29.":[459],"4-":[460],"Vamvakas":[461],"L,":[462],"Agelaki":[463],"S,":[464,511],"Kentepozidis":[465],"NK,":[466],"Pemetrexed":[469],"(MTA)":[470],"(ERL)":[474],"pretreated":[476],"(NSCLC):":[483],"randomized":[487,536],"III":[489],"Hellenic":[490],"Oncology":[491],"Research":[492],"Group":[493],"trial.":[494],"Proc":[495],"Am":[496],"Soc":[497],"Clin":[498],"28":[501],"(suppl):":[502],"abstr":[503],"7519.":[504],"5-":[505],"Cicenas":[510],"Efficacy":[514],"advanced,":[527],"poor":[532],"prognosis":[533],"(TITAN):":[534],"open-label,":[538],"2012;":[544],"DOI:10.1016/s1470-2045(11)70395-0":[545]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W367299136","counts_by_year":[{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
